Here are the latest items added to the CTN Dissemination Library for August-September 2023 (this post will be updated as new items come in): Capturing Drug Use Patterns at a Glance: An n-ary Word Sufficient Statistic for Repeated Univariate Categorical Values. Odom GJ, et al. PLoS One 2023 (in press). CTN-0094 Prevalence of Cannabis Use Disorder and Reasons for Use Among Adults in a US State Where Recreational Cannabis Use is Legal. Lapham GT, et al. JAMA Network Open 2023;6(8):e2328934. CTN-0077-Ot Integrative Data Analysis of Clinical Trials Network Studies to Examine the Impact of Psychosocial Treatments for Black People Who Use Cocaine: Study Protocol. Haeny AM, et al. Contemporary Clinical Trials 2023 (in press). CTN-0125 Naltrexone Plus Bupropion Reduces Cigarette Smoking in Individuals with Methamphetamine Use Disorder: A Secondary Analysis from the CTN ADAPT-2 Trial. Schmitz JM, et al. Journal of Substance Use and Addiction Treatment 2023;151:208987. NIDA-CTN-0068 Association Between Cannabis Use Disorder Symptom Severity and Probability of Clinically-Documented Diagnosis and Treatment in a Primary Care Sample. Matson TE, et al. Drug and Alcohol Dependence 2023:110946 (in press). CTN-0077-Ot Posted August 25, 2023

This post will contain a running list of all items added to the CTN Dissemination Library in July-August 2023. Castillo F, et al. Risks of Returning to Opioid Use at Treatment Entry and Early in Opioid Use Disorder Treatment: Role of Non-Opioid Substances. Drug and Alcohol Dependence 2023 (in press). CTN-0027, CTN-0030, CTN-0051 Parchman ML, et al. Supporting Practice Facilitators in a Learning Health Care System [commentary]. Permanente Journal 2023:23.035 Kidd JD, et al. Sexual Orientation Differences Among Men in a Randomized Clinical Trial of Extended-Release Naltrexone and Bupropion for Methamphetamine Use Disorder. Drug and Alcohol Dependence 2023; 250:110899. (CTN-0068) Trombello JM, et al. Psychometrics of the Concise Health Risk Tracking Self-Report (CHRT-SR16) Assessment of Suicidality in a Sample of Adults with Moderate to Severe Methamphetamine Use Disorder: Findings from the ADAPT-2 Randomized Trial. Neuropsychiatric Disease and Treatment 2023; 19:1443-1454. (CTN-0068)

New webinar recording available: Research 101 Session 2: FDA Basics & Essential Regulatory Compliance Description:This webinar outlines the basics of FDA oversight and reviews other essential regulatory activities to successfully keep a study in compliance, including ongoing management and reporting requirements. The regulatory portion reviews essential regulatory activities, such as IRB approvals and informed consent requirements. Lastly, there is a discussion of current challenges and best practices when working on regulatory compliance.  Check out the recording here! Posted July 7, 2023

May 1-31, 2023 Here are the newest items added to the Library in May 2023:

March-April 2023 Here are the newest items added to the Library in March and April 2023: Collaborative Care Programs for Pregnant and Postpartum Individuals with Opioid Use Disorder: Organizational Characteristics of Sites Participating in the NIDA CTN0080 MOMs Study. Kropp FB, et al. Journal of Substance Use and Addiction Treatment 2023;149:209030. CTN-0080 Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A Stepped Wedge Hybrid Type 1 Effectiveness-Implementation Study. Greiner MG, et al. Contemporary Clinical Trials 2023 (in press). CTN-0097 Optimizing Recruitment and Retention in Substance Use Disorder Research in Emergency Departments. Worth L, et al. West J Emerg Med 2023 (in press). CTN-0047 Repurposing Ketamine to Treat Cocaine Use Disorder: Integration of Artificial Intelligence-Based Prediction, Expert Evaluation, Clinical Corroboration, and Mechanism of Action Analyses. Gao X, et al. Addiction 2023 (in press). CTN-0114 Differential Symptom Weighting in Estimating Empirical Thresholds for Underlying PTSD Severity: Toward a “Platinum” Standard for Diagnosis? Morgan-Lopez A, et al. Int J Methods Psychiatr Res 2023;31963. CTN-0015 Estimating the Impact of Stimulant Use on Initiation of Buprenorphine and Extended-Release Naltrexone in Two Clinical Trials and Real-World Populations. Cook RR, et al. Addict Sci Clin Pract 2023;18:11. CTN-0051, CTN-0067 CTN Webinar: Research 101: Introduction to Clinical Trials: The Basics. Kim M & Vasquez M. Produced by the National Drug Abuse Treatment Clinical Trials Network’s Clinical Coordinating Center, March 3, 2023. Risk of Experiencing an Overdose Event for Patients Undergoing Treatment with Medication for Opioid Use Disorder. Brandt L, et al. Am J Psychiatry 2023 (in…

January 8, 2023 Added to the CTN Dissemination Library recently: Differential effects of patient navigation across latent profiles of barriers to care among people living with HIV and comorbid conditions.Traynor SM, et al. Journal of Clinical Medicine 2023;12:114. This paper reports on a study analyzing data from CTN-0049 (Project HOPE) to see if patient navigation interventions (with and without contingency management) are effective at increasing engagement in HIV care and viral suppression for people living with HIV. Find it in the CTN Dissemination Library. Baseline representativeness of patients in clinics enrolled in the PRimary care Opioid Use Disorders treatment (PROUD) trial: Comparison of trial and non-trial clinics in the same health systems.Wartko PD, et al. BMC Health Services Research 2022;2:1593. In this paper, researchers report on an analysis comparing patients in participating and non-participating clinics from the same health systems at baseline in the PROUD trial (CTN-0074) to see if there are any differences between patients in clinics willing and able to participate in trials and those that aren’t.